Merit Financial Group LLC Has $1.93 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Merit Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 123.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,231 shares of the biopharmaceutical company’s stock after purchasing an additional 2,341 shares during the quarter. Merit Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $1,930,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. OFI Invest Asset Management increased its position in shares of Alnylam Pharmaceuticals by 5.8% during the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 22 shares in the last quarter. Meridian Financial Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 28 shares during the period. Evelyn Partners Investment Management LLP increased its holdings in Alnylam Pharmaceuticals by 11.5% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 30 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the period. Finally, Sowell Financial Services LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. Sowell Financial Services LLC now owns 654 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 38 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $400.17 on Monday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The firm’s fifty day moving average price is $432.07 and its two-hundred day moving average price is $418.13. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The firm has a market capitalization of $52.87 billion, a P/E ratio of 1,667.38 and a beta of 0.32.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the sale, the executive vice president owned 21,264 shares in the company, valued at $9,615,155.52. This represents a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total value of $4,512,700.00. Following the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,517,119.43. This represents a 13.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 37,778 shares of company stock worth $17,096,988. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Jefferies Financial Group decreased their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Finally, Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Twenty-three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $477.44.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.